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economic consequences as hemodialysis patients. METHODS: A
total of 3067 adult predialysis patients with and without SHPT
were evaluated from January 1999 to December 2004 in a ret-
rospective matched cohort study using a patient-centric claims
database. Patients had a minimum 12-month pre-index and 6-
month follow-up after initial diagnosis of CKD and were
grouped into cohorts; cohort 1: without SHPT, cohort 2: with
SHPT. Annualized estimates of mean direct medical costs and
health care utilization, and time to dialysis or death following
index CKD diagnosis were compared. Generalized linear models
(GLM) with gamma distribution and a log link function were
used to assess differences in costs and GLM models with a neg-
ative binomial distribution were used to evaluate differences in
health care utilization. Kaplan-Meier survival analysis and Cox
proportional hazard models were used for time to dialysis and
death analysis. All multivariate models were adjusted for con-
founders: gender, age, plan type, payer type, geographic region,
physician specialty, pre-index co-morbidities, and pre-index total
health care costs. RESULTS: Generalized linear models revealed
CKD with SHPT had 3.61 times higher total costs, and 2.68
times more hospitalizations (p < 0.0001). Kaplan-Meier analysis
revealed that CKD with SHPT progresses more quickly to death
or dialysis. Cox models demonstrated that CKD with SHPT had
a signiﬁcantly higher risk of dialysis or death (HR = 5.05; 95%
CI = 4.08–6.24; p < 0.0001). CONCLUSION: SHPT in predial-
ysis patients without VDR activator therapy is associated with
signiﬁcantly greater direct total costs, inpatient hospitalizations,
and disease progression compared to patients without SHPT and
VDR activator therapy.
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OBJECTIVES: Chronic kidney disease (CKD) can adversely
affect workforce productivity and increase the economic burden
on employers. This analysis quantiﬁes the incremental direct
(medical, pharmacy) and indirect (sick leave, disability) health
care costs of pre-dialysis CKD patients from an employer’s per-
spective. METHODS: A retrospective analysis was conducted
using eligibility, medical, pharmacy and disability claims data
from 31 large US employers for approximately 5 million beneﬁ-
ciaries between January 1998 and January 2005. A total of
10,219 pre-dialysis CKD patients (deﬁned as ≥2 claims contain-
ing an ICD-9 diagnosis code for CKD less than 90 days apart,
with no history of organ transplant) were identiﬁed. These
patients were observed from the time (month) of their CKD diag-
nosis to the month preceding their ﬁrst renal dialysis claim, dis-
enrollment or study end date (whichever occurred ﬁrst). A
representative random sample of 171,207 individuals without
CKD was selected as controls. Employer costs were based on
direct medical and pharmacy costs as well as the indirect costs,
which measure employee productivity loss. Tobit regressions,
which correct for non-normality of costs, including controls for
age, gender, health plan, location, liver cirrhosis, hypertension,
chemotherapy, and Charlson Comorbidity Index, were con-
ducted. RESULTS: The unadjusted ratios of mean direct and
indirect costs for pre-dialysis CKD patients compared to controls
were 8.4 : 1 ($1671 vs. $200 per patient-month, p < 0.0001) and
5.8 : 1 ($406 vs. $70 per patient-month, p < 0.0001), respectively.
After controlling for confounding factors, the adjusted ratios
remained signiﬁcant at 4.3 : 1 ($651 incremental monthly cost, p
< 0.0001) for direct costs, and 3.3 : 1 ($157 incremental monthly
cost, p < 0.0001) for indirect costs. CONCLUSION: Both the
unadjusted and adjusted ratios for mean direct and indirect costs
for pre-dialysis CKD patients compared to non-CKD patients
indicated that pre-dialysis CKD resulted in statistically signiﬁ-
cant increases in both direct and indirect costs to the employer.
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OBJECTIVES: Anemia is a treatable and often preventable com-
plication of CKD, but is often under-diagnosed and under-
treated. This analysis evaluated the direct medical and indirect
work productivity (disability and sick leave) costs before and
after the diagnosis of anemia in pre-dialysis CKD patients.
METHODS: Anonymous health and disability claims from 31
U.S. employers between January 1998 and January 2006 from
∼5 million individuals were used to identify 3449 pre-dialysis
CKD patients <65 years of age with ≥2 anemia diagnosis claims.
The study period was deﬁned as the time from the ﬁrst CKD
claim until the earliest of disenrollment, initiation of dialysis,
organ transplantation, or study end. Average per member per
month (PMPM) costs were computed before and after the month
when anemia was ﬁrst diagnosed. All costs were calculated 
from employers’ perspectives. RESULTS: Average direct and
indirect PMPM costs were respectively $3293 and $501 three
months prior to the ﬁrst anemia diagnosis, $7445 and $838 
at the time of diagnosis, and $1794 and $365 twelve months
after diagnosis. Increases in inpatient costs were the largest driver
for the cost changes over time. Direct and indirect PMPM 
costs increased more than two-fold in the three months prior 
to the ﬁrst anemia diagnosis, leading to a cost peak at the time
of diagnosis, and gradually decreased over time to reach cost
levels similar to those observed twelve months before diagnosis.
CONCLUSION: Direct and indirect costs occurring as early 
as three months before the formal diagnosis of anemia in pre-
dialysis CKD patients could be associated with prodromes 
of anemia or late diagnosis. These costs peaked at time of diag-
nosis. Declining costs after diagnosis could suggest beneﬁts of
diagnosis and/or treatment of anemia. Further studies are needed
to evaluate whether earlier diagnosis and treatment of anemia
could reduce or prevent cost escalations in pre-dialysis CKD
patients.
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OBJECTIVES: Systemic lupus erythematosus (SLE) is an autoim-
mune disorder that can affect any system of the body. Kidney
Involvement, lupus nephritis (LN), affects up to 50% of SLE
patients during the course of their disease, and is characterised
by periods of active disease (ﬂares) and remission. For patients
